Combination Regimens of Radiation Therapy and Therapeutic Cancer Vaccines: Mechanisms and Opportunities

Seminars in Radiation Oncology

Volumn 25, Issue 1, 2015, Pages 46-53

  Garnett Benson, Charlie ^a   Hodge, James W ^b   Gameiro, Sofia R ^b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; PEPTIDE VACCINE; SIPULEUCEL T; VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMMUNOGENICITY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DOSE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TUMOR IMMUNITY; ANIMAL; MOUSE; NEOPLASMS; PROCEDURES;

ANIMALS; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; MICE; NEOPLASMS;

EID: 84919486724     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2014.07.002     Document Type: Review

References (67)

1. Kwilas A.R., Donahue R.N., Bernstein M.B., et al. In the field: Exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2012, 2:104.
2. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 2013, 105(4):256-265.
3. Bangia N., Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: Do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes?. Immunol Invest 2006, 35(3-4):485-503.
4. Leone P., Shin E.C., Perosa F., et al. MHC class I antigen processing and presenting machinery: Organization, function, and defects in tumor cells. J Natl Cancer Inst 2013, 105(16):1172-1187.
5. Poggi A., Musso A., Dapino I., et al. Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells. Immunol Lett 2014, 159(1-2):55-72.
6. Ahmed M.M., Hodge J.W., Guha C., et al. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res 2013, 1(5):280-284.
7. Deng L., Liang H., Burnette B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014, 124(2):687-695.
8. Draghiciu O., Walczak M., Hoogeboom B.N., et al. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer 2014, 134(4):859-872.
9. Kroemer G., Galluzzi L., Kepp O., et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
10. Heery C.R., Madan R.A., Bilusic M., et al. A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. J Clin Oncol 2013, 31(suppl 6). [abstr 102].
11. Hodge J.W., Kwilas A., Ardiani A., et al. Attacking malignant cells that survive therapy: Exploiting immunogenic modulation. Oncoimmunology 2013, 2(12):e26937.
12. Makinde A.Y., John-Aryankalayil M., Palayoor S.T., et al. Radiation survivors: Understanding and exploiting the phenotype following fractionated radiation therapy. Mol Cancer Res 2013, 11(1):5-12.
13. Friedman E.J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002, 8(19):1765-1780.
14. Janssens S., Tschopp J. Signals from within: The DNA-damage-induced NF-kappaB response. Cell Death Differ 2006, 13(5):773-784.
15. Gameiro S.R., Jammeh M.L., Wattenberg M.M., et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014, 5(2):403-416.
16. Garnett C.T., Palena C., Chakraborty M., et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64(21):7985-7994.
17. Ifeadi V., Garnett-Benson C. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS One 2012, 7(2):e31762.
18. Santin A.D., Hermonat P.L., Hiserodt J.C., et al. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. Int J Radiat Oncol Biol Phys 1997, 39(3):737-742.
19. Klein B., Loven D., Lurie H., et al. The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture. J Neurosurg 1994, 80(6):1074-1077.
20. Kumari A., Cacan E., Greer S., et al. Turning T cells on: Epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J Immunother Cancer 2013, 1:1-17.
21. Bernstein M.B., Garnett C.T., Zhang H., et al. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 2014, 29(4):153-161.
22. + T cells. J Leukoc Biol 2004, 75(5):785-791.
23. Vu M.D., Xiao X., Gao W., et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007, 110(7):2501-2510.
24. Valzasina B., Guiducci C., Dislich H., et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood 2005, 105(7):2845-2851.
25. Lugade A.A., Moran J.P., Gerber S.A., et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174(12):7516-7523.
26. Matsumura S., Wang B., Kawashima N., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008, 181(5):3099-3107.
27. Chakraborty M., Wansley E.K., Carrasquillo J.A., et al. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 2008, 14(13):4241-4249.
28. Ishikawa E., Tsuboi K., Saijo K., et al. X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions. Int J Radiat Oncol Biol Phys 2004, 59(5):1505-1512.
29. Chakraborty M., Abrams S.I., Coleman C.N., et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004, 64(12):4328-4337.
30. Reits E.A., Hodge J.W., Herberts C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203(5):1259-1271.
31. Liu R., Xiong S., Zhang L., et al. Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells. Cell Mol Immunol 2010, 7(2):157-162.
32. Schlom J. Therapeutic cancer vaccines: Current status and moving forward. J Natl Cancer Inst 2012, 104(8):599-613.
33. Kim K.W., Kim S.H., Shin J.G., et al. Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int J Cancer 2004, 109(5):685-690.
34. Wang Y.S., Tsang Y.W., Chi C.H., et al. Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cells. Cancer Lett 2008, 266(2):275-285.
35. Chi K.H., Liu S.J., Li C.P., et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005, 28(2):129-135.
36. Shibamoto Y., Okamoto M., Kobayashi M., et al. Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation. Mol Clin Oncol 2013, 1(4):649-654.
37. Vacchelli E., Vitale I., Tartour E., et al. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013, 2(9):e25595.
38. Sipuleucel-T with or without radiation therapy in treating patients with hormone-resistant metastatic prostate cancer. Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT01807065?term=NCT01807065&rank=1.
39. Sipuleucel-T and stereotactic ablative body radiation (SABR) for metastatic castrate-resistant prostate cancer (mCRPC). Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT01818986?term=NCT01818986&rank=1.
40. Radiation therapy in treating patients with metastatic hormone-resistant prostate cancer receiving sipuleucel-T. Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT01833208?term=NCT01833208&rank=1.
41. Radiation therapy and intratumoral autologous dendritic cells in soft tissue sarcomas (STS). Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT01347034?term=NCT01347034&rank=1.
42. Study of DC vaccination against glioblastoma. Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT01567202?term=NCT01567202&rank=1.
43. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993, 90(8):3539-3543.
44. Mach N., Gillessen S., Wilson S.B., et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000, 60(12):3239-3246.
45. Newcomb E.W., Demaria S., Lukyanov Y., et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res 2006, 12(15):4730-4737.
46. Pancreatic tumor cell vaccine (GVAX), low dose cyclophosphamide, fractionated stereotactic body radiation therapy (SBRT), and FOLFIRINOX chemotherapy in patients with resected adenocarcinoma of the pancreas. Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT01595321?term=NCT01595321&rank=1.
47. Hodge J.W., McLaughlin J.P., Kantor J.A., et al. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997, 15(6-7):759-768.
48. Chakraborty M., Gelbard A., Carrasquillo J.A., et al. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother 2008, 57(8):1173-1183.
49. Hodge J.W., Sharp H.J., Gameiro S.R. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm 2012, 27(1):12-22.
50. Gulley J.L., Arlen P.M., Bastian A., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005, 11(9):3353-3362.
51. Lechleider R.J., Arlen P.M., Tsang K.Y., et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008, 14(16):5284-5291.
52. Kamrava M., Kesarwala A.H., Madan R.A., et al. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer Prostatic Dis 2012, 15(3):289-295.
53. Garnett C.T., Greiner J.W., Tsang K.Y., et al. TRICOM vector based cancer vaccines. Curr Pharm Des 2006, 12(3):351-361.
54. Gulley J.L., Madan R.A., Tsang K.Y., et al. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther 2011, 11(11):1409-1418.
55. Gulley J.L., Heery C.R., Madan R.A., et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother 2013, 62(9):1521-1531.
56. Kudo-Saito C., Schlom J., Hodge J.W. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005, 11(6):2416-2426.
57. Phase 1b study of AdV-tk + valacyclovir combined with radiation therapy for malignant gliomas (BrTK01). Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT00751270?term=NCT00751270&rank=1.
58. Phase 3 study of ProstAtak™ with standard radiation therapy for localized prostate cancer (PrTK03). Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT01436968?term=NCT01436968&rank=1.
59. Ye G.W., Park J.B., Park Y.J., et al. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. Mol Ther 2007, 15(8):1564-1570.
60. Weng D., Song B., Koido S., et al. Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation. J Immunol 2013, 191(2):755-763.
61. Iinuma H., Fukushima R., Inaba T., et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med 2014, 12(1):84.
62. Vaccine therapy, temozolomide, and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme. Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT01222221?term=NCT01222221&rank=1.
63. Effects of vaccinations with HLA-A2-restricted glioma antigen-peptides in combination with poly-ICLC for adults with high-risk WHO grade II astrocytomas and oligo-astrocytomas. Available from: , 2014. http://clinicaltrials.gov/ct2/show/NCT00795457?term=NCT00795457&rank=1.
64. Tseng C.W., Trimble C., Zeng Q., et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2009, 58(5):737-748.
65. Chamoto K., Takeshima T., Wakita D., et al. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. Cancer Sci 2009, 100(5):934-939.
66. Sega E.I., Lu Y., Ringor M., et al. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy. Int J Radiat Oncol Biol Phys 2008, 71(2):559-566.
67. Hannan R., Zhang H., Wallecha A., et al. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immunol Immunother 2012, 61(12):2227-2238.